S. Michael Owens
Professor
Also affiliated: University of North Carolina at Chapel Hill (1981); Pennsylvania State University (2011–2014); Children's Hospital of Philadelphia (2020); University of Arizona (1982–1986); Georgetown University (2005); Toronto Western Hospital (2007); University of Arkansas Medical Center (1986–2019); Georgetown University Medical Center (2005); Society of Toxicology (2011); University of Florida (1991); Office of the Chief Medical Examiner (1983); InterveXion Therapeutics (United States) (2014–2019); The Christie Hospital (1995); The Christie NHS Foundation Trust (1995); Society of Environmental Toxicology and Chemistry (2011); Mayo Clinic in Florida (2011); Arkansas Department of Agriculture (2006–2014); Institute of Pharmacology (2008–2011); Case Western Reserve University (2005); University of Pennsylvania (2020); Florida College (1991)
Faculty Researcher
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
S. Michael Owens' research at the University of Arkansas for Medical Sciences focuses on the pharmacological effects of substances, particularly in animal models. His work has investigated the dose-response relationships of drugs such as phencyclidine and methamphetamine, utilizing monoclonal antibodies in these studies. Owens' research also extends to the use of Sprague-Dawley rats as a model organism to understand drug mechanisms and effects. With a career spanning over 130 publications and accumulating over 3,500 citations, his scholarly contributions have been recognized with a designation as a highly cited researcher. His work has been characterized by a consistent engagement with preclinical drug research, contributing to the broader understanding of substance action and potential therapeutic interventions.
Metrics
- h-index: 36
- Publications: 134
- Citations: 3,551
Selected Publications
-
Active vaccination reduces reinforcing effects of MDPV in male Sprague-Dawley rats trained to self-administer cocaine (2020)
-
The Development and Characterization of an scFv-Fc Fusion–Based Gene Therapy to Reduce the Psychostimulant Effects of Methamphetamine Abuse (2020)
-
Pharmacokinetic, Cardiovascular and Locomotor Effects of alpha‐Pyrrolidinopentiophenone (alpha‐PVP) in Male Sprague Dawley Rats after Active Vaccination (2019)
-
Effects of a methamphetamine vaccine, IXT-v100, on methamphetamine-related behaviors (2019)
-
Design, synthesis and biological evaluation of a bi-specific vaccine against α-pyrrolidinovalerophenone (α-PVP) and 3,4-methylenedioxypyrovalerone (MDPV) in rats (2019)
-
Antibody production and pharmacokinetics of METH in rats following vaccination with the METH vaccine, IXT-v100, adjuvanted with GLA-SE (2019)
-
Effect of Bile Duct Ligation-induced Liver Dysfunction on Methamphetamine Pharmacokinetics and Locomotor Activity in Rats (2019)
-
The development and characterization of an scFv-Fc fusion based gene therapy to reduce the psychostimulant effects of methamphetamine abuse (2019)
-
In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome (2019)
-
Cardiovascular effects of 3,4-methylenedioxypyrovalerone (MDPV) in male and female Sprague-Dawley rats (2019)
-
Anti‐Methamphetamine Antibody Gene Therapy Ameliorates Methamphetamine‐induced Locomotor Effects in Mice for 8 Months after a Single Treatment (2018)
-
Organ Distribution and Clearance of (3,4)‐Methylenedioxypyrovalerone (MDPV) Enantiomers in Female and Male Rats after Intravenous Administration of Racemic MDPV (2018)
-
Development and Preclinical Testing of a Vaccine for 3,4‐Methylenedioxypyrovalerone (( <i>R,S</i> )‐MDPV) Substance Use Disorders (2018)
-
Development and testing of AAV-delivered single-chain variable fragments for the treatment of methamphetamine abuse (2018)
-
The Role of Norbuprenorphine in Buprenorphine‐Induced Neonatal Abstinence Syndrome: A Pilot Study (2017)
Similar Researchers
Based on overlapping research topics